Curis, Inc. (NASDAQ: CRIS) today announced initiation of patient dosing in a Phase 1 trial of CA-4948, an orally available ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE